BriaCell presents anti-cancer activity of Bria-OTS at SITC 2025

BriaCell (BCTX) Therapeutics announces that the Company is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer, SITC, 40th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD. Summary of Preclinical Findings: Bria-BRES+ and Bria-PROS+ rapidly activated key components of the immune system in preclinical models. The platform induced coordinated innate and adaptive immune responses, training the immune system to kill cancer cells. Both Bria-BRES+ and Bria-PROS+ produced sustained, and durable anti-cancer immune responses that may translate into prolonged clinical benefit for patients treated with the Bria-OTS+ platform of whole cell immunotherapies. Positive results with lead candidates Bria-BRES+ and Bria-PROS+ reinforce the broad applicability of the Bria-OTS+ platform and support possible expansion into other solid tumor indications.